688617 惠泰医疗
已收盘 11-20 15:00:01
资讯
新帖
简况
惠泰医疗：公司胸主动脉腹膜支架自获证后，已经在全国二十余省实现招标挂网
每日经济新闻 · 11-20 17:46
惠泰医疗：公司胸主动脉腹膜支架自获证后，已经在全国二十余省实现招标挂网
惠泰医疗大涨 国产器械前景佳
智选洞察 · 11-20 10:02
惠泰医疗大涨 国产器械前景佳
惠泰医疗：公司近期与投资者交流的内容已根据相关规则进行披露
证券之星 · 11-12
惠泰医疗：公司近期与投资者交流的内容已根据相关规则进行披露
惠泰医疗大幅上涨 中国医疗器械企业出海扩大国际贸易
智选洞察 · 11-12
惠泰医疗大幅上涨 中国医疗器械企业出海扩大国际贸易
惠泰医疗（688617）11月11日主力资金净卖出1931.34万元
证券之星 · 11-12
惠泰医疗（688617）11月11日主力资金净卖出1931.34万元
惠泰医疗：新品持续获批 业绩增速强劲
招商证券 · 11-11
惠泰医疗：新品持续获批 业绩增速强劲
惠泰医疗（688617）11月6日主力资金净卖出2379.62万元
证券之星 · 11-07
惠泰医疗（688617）11月6日主力资金净卖出2379.62万元
惠泰医疗（688617）11月4日主力资金净卖出168.88万元
证券之星 · 11-05
惠泰医疗（688617）11月4日主力资金净卖出168.88万元
【机构调研记录】南方基金调研周大生、惠泰医疗等18只个股（附名单）
证券之星 · 11-04
【机构调研记录】南方基金调研周大生、惠泰医疗等18只个股（附名单）
【机构调研记录】华泰柏瑞基金调研高测股份、惠泰医疗等4只个股（附名单）
证券之星 · 11-04
【机构调研记录】华泰柏瑞基金调研高测股份、惠泰医疗等4只个股（附名单）
太平洋：给予惠泰医疗买入评级
证券之星 · 11-01
太平洋：给予惠泰医疗买入评级
太平洋给予惠泰医疗买入评级，惠泰医疗点评报告：业绩基本符合预期，看好集采下产品放量
每日经济新闻 · 11-01
太平洋给予惠泰医疗买入评级，惠泰医疗点评报告：业绩基本符合预期，看好集采下产品放量
惠泰医疗：10月29日接受机构调研，宝盈基金管理有限公司、华泰柏瑞基金管理有限公司等多家机构参与
证券之星 · 11-01
惠泰医疗：10月29日接受机构调研，宝盈基金管理有限公司、华泰柏瑞基金管理有限公司等多家机构参与
惠泰医疗（688617）6.5万股限售股将于11月1日解禁，占总股本0.07%
证券之星 · 11-01
惠泰医疗（688617）6.5万股限售股将于11月1日解禁，占总股本0.07%
华安证券给予惠泰医疗买入评级，2024Q3业绩延续高增长，降本增效效果显著
每日经济新闻 · 10-31
华安证券给予惠泰医疗买入评级，2024Q3业绩延续高增长，降本增效效果显著
华安证券：给予惠泰医疗买入评级
证券之星 · 10-31
华安证券：给予惠泰医疗买入评级
惠泰医疗：公司未通过港股通渠道增持港股公司的股份
证券之星 · 10-31
惠泰医疗：公司未通过港股通渠道增持港股公司的股份
东吴证券：给予惠泰医疗买入评级
证券之星 · 10-30
东吴证券：给予惠泰医疗买入评级
平安证券给予惠泰医疗推荐评级 心血管介入领域领军企业 快速成长进行时
每日经济新闻 · 10-28
平安证券给予惠泰医疗推荐评级 心血管介入领域领军企业 快速成长进行时
平安证券：给予惠泰医疗增持评级
证券之星 · 10-28
平安证券：给予惠泰医疗增持评级
加载更多
公司概况
公司名称：
深圳惠泰医疗器械股份有限公司
所属行业：
专用设备制造业
上市日期：
2021-01-07
主营业务：
深圳惠泰医疗器械股份有限公司的主营业务为心血管介入医疗器械的研发、生产和销售；主要产品是电生理、冠脉通路、外周血管介入、非血管介入医疗器械。公司的电生理电极导管和射频消融电极导管均为国内首个获批上市的国产产品，先发优势助力公司成为国内电生理市场中国生产厂商的龙头企业。
发行价格：
74.46
{"stockData":{"symbol":"688617","market":"SH","secType":"STK","nameCN":"惠泰医疗","latestPrice":372.58,"timestamp":1732086001000,"preClose":350.23,"halted":0,"volume":1062057,"delay":0,"floatShares":97393799,"shares":97393799,"eps":6.7646,"marketStatus":"已收盘","marketStatusCode":5,"change":22.35,"latestTime":"11-20 15:00:01","open":347.11,"high":374.93,"low":347.11,"amount":390000000,"amplitude":0.0794,"askPrice":372.6,"askSize":2,"bidPrice":372.58,"bidSize":0,"shortable":0,"etf":0,"ttmEps":6.7646,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732152600000},"adr":0,"adjPreClose":350.23,"symbolType":"stock_kcb","openAndCloseTimeList":[[1732066200000,1732073400000],[1732078800000,1732086000000]],"highLimit":385.25,"lowLimit":315.21,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":97393764,"pbRate":15.19,"roa":"--","roe":"24.39%","epsLYR":8.04,"committee":-0.047619,"marketValue":36287000000,"floatMarketCap":36287000000,"peRate":55.077907,"changeRate":0.0638,"turnoverRate":0.0109,"status":0,"afterMarket":{"amount":0,"volume":0,"close":372.58,"buyVolume":0,"sellVolume":268,"time":1732088039464,"indexStatus":"已收盘 11-20 15:30:00","preClose":350.23}},"requestUrl":"/m/hq/s/688617","defaultTab":"news","newsList":[{"id":"2484167214","title":"惠泰医疗：公司胸主动脉腹膜支架自获证后，已经在全国二十余省实现招标挂网","url":"https://stock-news.laohu8.com/highlight/detail?id=2484167214","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484167214?lang=zh_cn&edition=full","pubTime":"2024-11-20 17:46","pubTimestamp":1732095961,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：请问，贵公司4月份获批了胸主动脉覆膜支架，开辟了进军主动脉夹层的新赛道， 请问7个月过去了，这款产品开始商业化临床植入没有？预计2024年能有多少植入量？公司制订了赶超国内头部心脉医疗，先健科技的计划表没有？惠泰医疗（688617.SH）11月20日在投资者互动平台表示，公司胸主动脉腹膜支架自获证后，已经在全国二十余省实现招标挂网，并在全国多个省份、医院实现商业植入，目前正在稳步推进。公司会结合自身的优势，并持续学习优秀企业的研发及推广经验，加速自身成长。(记者 蔡鼎)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120174708abd19cf6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120174708abd19cf6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688617","BK0251"],"gpt_icon":0},{"id":"2484133804","title":"惠泰医疗大涨 国产器械前景佳","url":"https://stock-news.laohu8.com/highlight/detail?id=2484133804","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484133804?lang=zh_cn&edition=full","pubTime":"2024-11-20 10:02","pubTimestamp":1732068122,"startTime":"0","endTime":"0","summary":"11月20日，惠泰医疗股价大幅上涨，截至10点02分，惠泰医疗上涨5.01%，报367.78元/股，成交1.37亿元，换手率0.39%。资金动向截止发稿，惠泰医疗获得主力净流入1513万元，其中超大单流入828万元，大单流入684万元。主营业务及业绩惠泰医疗公司主营业务为电生理和血管介入医疗器械的研发、生产和销售。最新财报显示，今年三季报，惠泰医疗实现营业收入15.25亿元，同比增长25.63%，净利润为5.28亿元，同比增长30.97%，基本每股收益为5.44元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120100233a24736bd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120100233a24736bd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688617"],"gpt_icon":0},{"id":"2482987776","title":"惠泰医疗：公司近期与投资者交流的内容已根据相关规则进行披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2482987776","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482987776?lang=zh_cn&edition=full","pubTime":"2024-11-12 18:00","pubTimestamp":1731405639,"startTime":"0","endTime":"0","summary":"证券之星消息，惠泰医疗11月12日在投资者关系平台上答复投资者关心的问题。公司近期与投资者交流的内容已根据相关规则进行披露。目前，公司的冲击波球囊处于临床准备阶段。截至目前，迈瑞与惠泰在整合协同工作中的关联交易是由迈瑞向惠泰提供研发服务、营销服务产生的，故惠泰是买方，迈瑞是提供服务方。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111200030328.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688617","BK0251"],"gpt_icon":0},{"id":"2482771586","title":"惠泰医疗大幅上涨 中国医疗器械企业出海扩大国际贸易","url":"https://stock-news.laohu8.com/highlight/detail?id=2482771586","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482771586?lang=zh_cn&edition=full","pubTime":"2024-11-12 09:58","pubTimestamp":1731376713,"startTime":"0","endTime":"0","summary":"11月12日，惠泰医疗股价大幅上涨，截至09点58分，惠泰医疗上涨5.13%，报349.88元/股，成交2.13亿元，换手率0.64%，振幅5.84%。资金动向截止发稿，惠泰医疗获得主力净流入988万元，其中超大单流入796万元，大单流入191万元。主营业务及业绩惠泰医疗公司主营业务为电生理和血管介入医疗器械的研发、生产和销售。最新财报显示，今年三季报，惠泰医疗实现营业收入15.25亿元，同比增长25.63%，净利润为5.28亿元，同比增长30.97%，基本每股收益为5.44元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112095944abb7a2d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112095944abb7a2d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688617","BK0251","159883"],"gpt_icon":0},{"id":"2482796276","title":"惠泰医疗（688617）11月11日主力资金净卖出1931.34万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2482796276","media":"证券之星","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482796276?lang=zh_cn&edition=full","pubTime":"2024-11-12 08:24","pubTimestamp":1731371077,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年11月11日收盘，惠泰医疗报收于332.8元，下跌1.83%，换手率1.45%，成交量1.41万手，成交额4.71亿元。近5日资金流向一览见下表：惠泰医疗融资融券信息显示，融资方面，当日融资买入3228.45万元，融资偿还1715.12万元，融资净买入1513.33万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111200006771.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688617"],"gpt_icon":0},{"id":"2482274825","title":"惠泰医疗：新品持续获批 业绩增速强劲","url":"https://stock-news.laohu8.com/highlight/detail?id=2482274825","media":"招商证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482274825?lang=zh_cn&edition=full","pubTime":"2024-11-11 00:00","pubTimestamp":1731254400,"startTime":"0","endTime":"0","summary":"公司发布2024 年第三季度报告：2024 年前三季度实现营业收入15.25 亿元，同比增长25.63%；归母净利润5.28 亿元，同比增长30.97%；扣非归母净利润5.08 亿元，同比增长41.08%。其中，2024 年第三季度营业收入5.24 亿元，同比增长23.05%；归母净利润1.86 亿元，同比增长27.24%；扣非归母净利润1.80 亿元，同比增长53.18%。电生理产品进展顺利，期待房颤新品获批。血管介入新品持续获批，进一步向临床传递全产品解决方案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202411111631219f5957c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202411111631219f5957c7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688617","BK0251"],"gpt_icon":0},{"id":"2481998585","title":"惠泰医疗（688617）11月6日主力资金净卖出2379.62万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481998585","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481998585?lang=zh_cn&edition=full","pubTime":"2024-11-07 08:20","pubTimestamp":1730938850,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年11月6日收盘，惠泰医疗报收于331.96元，下跌4.25%，换手率1.81%，成交量1.76万手，成交额5.96亿元。近5日资金流向一览见下表：惠泰医疗融资融券信息显示，融资方面，当日融资买入4692.81万元，融资偿还2527.46万元，融资净买入2165.36万元，连续3日净买入累计1.19亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110700007084.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688617"],"gpt_icon":0},{"id":"2481560766","title":"惠泰医疗（688617）11月4日主力资金净卖出168.88万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481560766","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481560766?lang=zh_cn&edition=full","pubTime":"2024-11-05 08:21","pubTimestamp":1730766089,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年11月4日收盘，惠泰医疗报收于360.01元，下跌4.56%，换手率0.93%，成交量9056.0手，成交额3.3亿元。近5日资金流向一览见下表：惠泰医疗融资融券信息显示，融资方面，当日融资买入5856.36万元，融资偿还1248.61万元，融资净买入4607.75万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110500007031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688617","BK0251"],"gpt_icon":0},{"id":"2480311862","title":"【机构调研记录】南方基金调研周大生、惠泰医疗等18只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2480311862","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480311862?lang=zh_cn&edition=full","pubTime":"2024-11-04 08:02","pubTimestamp":1730678548,"startTime":"0","endTime":"0","summary":"2）惠泰医疗 惠泰医疗2024年三季报显示，公司主营收入15.25亿元，同比上升25.63%；归母净利润5.28亿元，同比上升30.97%；扣非净利润5.08亿元，同比上升41.08%；其中2024年第三季度，公司单季度主营收入5.24亿元，同比上升23.05%；单季度归母净利润1.86亿元，同比上升27.24%；单季度扣非净利润1.8亿元，同比上升53.18%；负债率13.12%，投资收益1148.47万元，财务费用-512.35万元，毛利率72.69%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110400001483.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002867","BK0251","BK0197","BK0127","BK0262","688617"],"gpt_icon":0},{"id":"2480319073","title":"【机构调研记录】华泰柏瑞基金调研高测股份、惠泰医疗等4只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2480319073","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480319073?lang=zh_cn&edition=full","pubTime":"2024-11-04 08:02","pubTimestamp":1730678537,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及11月1日披露的机构调研信息，华泰柏瑞基金近期对4家上市公司进行了调研，相关名单如下：1）高测股份 个股亮点：公司主要经营的产品为高硬脆特性材料切割装备、切割耗材和轮胎成品测试装备。3）路维光电 个股亮点：公司是大尺寸铬版光罩领域领先企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110400001470.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688556","BK0251","688617"],"gpt_icon":0},{"id":"2480889777","title":"太平洋：给予惠泰医疗买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2480889777","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480889777?lang=zh_cn&edition=full","pubTime":"2024-11-01 21:46","pubTimestamp":1730468764,"startTime":"0","endTime":"0","summary":"太平洋证券股份有限公司谭紫媚近期对惠泰医疗进行研究并发布了研究报告《惠泰医疗点评报告：业绩基本符合预期，看好集采下产品放量》，本报告对惠泰医疗给出买入评级，当前股价为377.23元。维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有15家机构给出评级，买入评级12家，增持评级3家；过去90天内机构目标均价为455.0。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110100047690.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601099","688617"],"gpt_icon":0},{"id":"2480881617","title":"太平洋给予惠泰医疗买入评级，惠泰医疗点评报告：业绩基本符合预期，看好集采下产品放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2480881617","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480881617?lang=zh_cn&edition=full","pubTime":"2024-11-01 21:46","pubTimestamp":1730468760,"startTime":"0","endTime":"0","summary":"太平洋11月01日发布研报称，给予惠泰医疗（688617.SH，最新价：377.23元）买入评级。评级理由主要包括：1）电生理集采续约情况良好，冠脉通路集采助力产品入院；2）PFA相关工作进展顺利，公司加速进军房颤领域；3）期间费用管理成效显著，盈利能力持续提升。风险提示：创新技术与产品的研发风险，核心技术人才流失风险，经营渠道管理风险，产品质量及潜在责任风险，市场竞争风险。AI点评：惠泰医疗近一个月获得4份券商研报关注，买入3家。（文章来源：每日经济新闻）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101215227a2096299&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101215227a2096299&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["601099","688617"],"gpt_icon":0},{"id":"2480070851","title":"惠泰医疗：10月29日接受机构调研，宝盈基金管理有限公司、华泰柏瑞基金管理有限公司等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2480070851","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480070851?lang=zh_cn&edition=full","pubTime":"2024-11-01 17:55","pubTimestamp":1730454945,"startTime":"0","endTime":"0","summary":"预计在2025年，海外业务基本上会保持较高增长。三季度手术量约为3,900例，尽管同比增长25%，但仍低于预期。截至目前，累计完成11,356台手术，全年18,000台的预期需要进行调整，预计将完成15,000多台手术。公司三季度市场完成22台设备装机，今年已累计完成设备装机135台，预计全年完成设备装机150台。公司在获得关联交易批准后，全面投入协同工作，在确保产品按时上市的基础上，将根据临床反馈持续进行产品迭代。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110100035972.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688617"],"gpt_icon":0},{"id":"2480909095","title":"惠泰医疗（688617）6.5万股限售股将于11月1日解禁，占总股本0.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480909095","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480909095?lang=zh_cn&edition=full","pubTime":"2024-11-01 08:06","pubTimestamp":1730419581,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，惠泰医疗于11月1日将有6.5万股限售股份解禁，为公司股权激励一般股份，占公司总股本0.07%。最近一年内，该股累计解禁2205.44万股，占总股本的22.64%。惠泰医疗主营业务：公司是一家专注于电生理和血管介入医疗器械的研发、生产和销售的高新技术企业,已形成了以完整冠脉通路和电生理医疗器械为主导,外周血管和神经介入医疗器械为重点发展方向的业务布局。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110100009291.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688617"],"gpt_icon":0},{"id":"2479857300","title":"华安证券给予惠泰医疗买入评级，2024Q3业绩延续高增长，降本增效效果显著","url":"https://stock-news.laohu8.com/highlight/detail?id=2479857300","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479857300?lang=zh_cn&edition=full","pubTime":"2024-10-31 20:05","pubTimestamp":1730376329,"startTime":"0","endTime":"0","summary":"华安证券10月31日发布研报称，给予惠泰医疗（688617.SH，最新价：371.5元）买入评级。评级理由主要包括：1）费用控制良好，单Q3毛利率及净利率均有提升；2）关注福建电生理集采进展，以及公司房颤手术创新产品上市情况。风险提示：公司手术量拓展不及预期风险。公司在研临床进展不及预期风险。AI点评：惠泰医疗近一个月获得2份券商研报关注，买入1家。文章来源：每日经济新闻原标题：华安证券给予惠泰医疗买入评级，2024Q3业绩延续高增长，降本增效效果显著","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241031201018a201a6d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241031201018a201a6d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688617","600909"],"gpt_icon":0},{"id":"2479408398","title":"华安证券：给予惠泰医疗买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2479408398","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479408398?lang=zh_cn&edition=full","pubTime":"2024-10-31 20:01","pubTimestamp":1730376104,"startTime":"0","endTime":"0","summary":"华安证券股份有限公司谭国超,李婵近期对惠泰医疗进行研究并发布了研究报告《2024Q3业绩延续高增长，降本增效效果显著》，本报告对惠泰医疗给出买入评级，当前股价为371.5元。 惠泰医疗 主要观点： 事件： 公司发布2024年三季报，前三季度公司实现营业收入15.25亿元，归母净利润5.28亿元。最新盈利预测明细如下：该股最近90天内共有15家机构给出评级，买入评级12家，增持评级3家；过去90天内机构目标均价为455.0。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100040944.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688617","600909"],"gpt_icon":0},{"id":"2479509083","title":"惠泰医疗：公司未通过港股通渠道增持港股公司的股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2479509083","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479509083?lang=zh_cn&edition=full","pubTime":"2024-10-31 20:00","pubTimestamp":1730376014,"startTime":"0","endTime":"0","summary":"证券之星消息，惠泰医疗10月31日在投资者关系平台上答复投资者关心的问题。公司未通过港股通渠道增持港股公司的股份。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100040875.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["HSTECH","688617","BK0251","HSCEI"],"gpt_icon":0},{"id":"2479231766","title":"东吴证券：给予惠泰医疗买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2479231766","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479231766?lang=zh_cn&edition=full","pubTime":"2024-10-30 00:31","pubTimestamp":1730219476,"startTime":"0","endTime":"0","summary":"东吴证券股份有限公司朱国广近期对惠泰医疗进行研究并发布了研究报告《2024三季报点评：收入符合预期，看好未来成长》，本报告对惠泰医疗给出买入评级，当前股价为375.48元。 单Q3业绩受院内手术淡季影响，环比Q2略下降。单Q3收入环比Q2下降3.99pct，归母净利润环比Q2下降8.31pct，扣非归母净利润环比Q2下降5.68pct。最新盈利预测明细如下：该股最近90天内共有15家机构给出评级，买入评级12家，增持评级3家；过去90天内机构目标均价为455.0。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000000206.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601555","688617"],"gpt_icon":0},{"id":"2478212442","title":"平安证券给予惠泰医疗推荐评级 心血管介入领域领军企业 快速成长进行时","url":"https://stock-news.laohu8.com/highlight/detail?id=2478212442","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478212442?lang=zh_cn&edition=full","pubTime":"2024-10-28 15:11","pubTimestamp":1730099475,"startTime":"0","endTime":"0","summary":"平安证券10月28日发布研报称，给予惠泰医疗（688617.SH，最新价：386.23元）推荐评级。评级理由主要包括：1）公司深耕心脏电生理和血管介入器械领域，产品优势显著，得到市场广泛认可；2）电生理：从耗材到整体解决方案，全面布局射频与PFA系统；3）冠脉通路：始于集采，基于质量，快速放量中；4）外周介入：持续扩展，打造新的增长曲线。风险提示：1）产品销售不及预期；2）新产品研发进展不及预期；3）国家集采政策的影响等。AI点评：惠泰医疗近一个月获得1份券商研报关注。文章来源：每日经济新闻原标题：平安证券给予惠泰医疗推荐评级，心血管介入领域领军企业，快速成长进行时","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241028153036a1f1047a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241028153036a1f1047a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688617","161027"],"gpt_icon":0},{"id":"2478121714","title":"平安证券：给予惠泰医疗增持评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2478121714","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478121714?lang=zh_cn&edition=full","pubTime":"2024-10-28 15:06","pubTimestamp":1730099185,"startTime":"0","endTime":"0","summary":"平安证券股份有限公司叶寅,倪亦道,裴晓鹏近期对惠泰医疗进行研究并发布了研究报告《心血管介入领域领军企业，快速成长进行时》，本报告对惠泰医疗给出增持评级，当前股价为386.23元。心脏电生理术式主要用于过速性心律失常病症的介入治疗。首次覆盖，给予\"推荐\"评级。最新盈利预测明细如下：该股最近90天内共有14家机构给出评级，买入评级12家，增持评级2家；过去90天内机构目标均价为455.0。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102800013172.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688617"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2021-01-07","address":"广东省深圳市南山区西丽街道松坪山社区松坪山朗山路11号同方信息港B栋601","stockEarnings":[{"period":"1week","weight":0.0819},{"period":"1month","weight":0.0124},{"period":"3month","weight":0.0236},{"period":"6month","weight":0.0521},{"period":"1year","weight":0.5614},{"period":"ytd","weight":0.3965}],"companyName":"深圳惠泰医疗器械股份有限公司","boardCode":"AI0035","perCapita":"24378股","boardName":"专用设备制造业","registeredCapital":"9739万元","compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":0.0306},{"period":"3month","weight":0.1823},{"period":"6month","weight":0.0904},{"period":"1year","weight":0.0978},{"period":"ytd","weight":0.1321}],"survey":" 深圳惠泰医疗器械股份有限公司的主营业务为心血管介入医疗器械的研发、生产和销售；主要产品是电生理、冠脉通路、外周血管介入、非血管介入医疗器械。公司的电生理电极导管和射频消融电极导管均为国内首个获批上市的国产产品，先发优势助力公司成为国内电生理市场中国生产厂商的龙头企业。","serverTime":1732124477802,"listedPrice":74.46,"stockholders":"3995人(较上一季度增加17.64%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"惠泰医疗(688617)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供惠泰医疗(688617)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"惠泰医疗,688617,惠泰医疗股票,惠泰医疗股票老虎,惠泰医疗股票老虎国际,惠泰医疗行情,惠泰医疗股票行情,惠泰医疗股价,惠泰医疗股市,惠泰医疗股票价格,惠泰医疗股票交易,惠泰医疗股票购买,惠泰医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"惠泰医疗(688617)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供惠泰医疗(688617)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}